The difference between 503A and 503B comes down to who a compounded medication is made for and who oversees the process. 503A pharmacies prepare medications for individual patients with a prescription and answer primarily to state boards of pharmacy. 503B outsourcing facilities register with the FDA, follow manufacturer-style quality rules, and can supply clinics and hospitals. Neither is FDA-approved, neither is automatically better, and both can be verified.
In 2012, contaminated steroid injections from a single Massachusetts compounder caused 753 infections and 64 deaths across 20 states. A year later, Congress divided compounders into two federal categories, and the difference between 503A and 503B pharmacies is still based on who the medicine is made for and who inspects the process.
Compounding itself is straightforward to describe. A pharmacist combines, mixes, or alters ingredients to create a medication for a need that a commercial product doesn’t meet, such as a different strength, a dye-free formula, or a liquid instead of a tablet. The rules around it are harder to follow.
If you’ve seen “503A” or “503B” on a telehealth ad, a pharmacy website, or in a news story, you’re not alone in wondering what those numbers mean for safety. This guide explains the origins of the two categories, what each is allowed to do, and how to check which kind of pharmacy you’re using, with practical notes for prescribers along the way.
Why Compounding Law Split in Two After 2012
Federal law recognizes two compounding pathways because a 2012 outbreak exposed a pharmacy operating at a manufacturer’s scale without a manufacturer’s oversight. The Drug Quality and Security Act of 2013 kept traditional pharmacy compounding under Section 503A and created a new, voluntary Section 503B category for larger “outsourcing facilities.”
The NECC Outbreak in Brief
The pharmacy at the center was New England Compounding Center (NECC) in Framingham, Massachusetts. According to the CDC’s archived outbreak report, patients developed fungal meningitis and other infections after receiving preservative-free methylprednisolone acetate injections, a steroid often used for back and joint pain.
NECC recalled three lots on September 26, 2012, then expanded the recall to all of its products on October 6. The outbreak ultimately affected patients in 20 states.
What the Drug Quality and Security Act Changed
The FDA’s overview of human drug compounding laws notes that the Drug Quality and Security Act was enacted on November 27, 2013. It added Section 503B, a voluntary category for outsourcing facilities that choose to register with the FDA and meet stricter federal standards.
The law also cleaned up Section 503A by removing advertising provisions that courts had found unconstitutional. That change clarified that 503A applies nationwide, which set up the 503A vs. 503B split that still exists today.
What a 503A Compounding Pharmacy Does
A 503A compounding pharmacy prepares medications for an individual, identified as a patient based on a valid prescription. These pharmacies are licensed and primarily overseen by state boards of pharmacy, follow the USP compounding standards their state enforces, and are exempt from FDA approval, certain labeling rules, and federal manufacturing requirements.
This is the model most people picture when they think of a local compounding pharmacy, and King’s explains how compounding works in more detail.
Patient-Specific by Design
Under the FD&C Act provisions that apply to compounding, 503A compounding has to be tied to a prescription for a named patient. The FDA’s guidance on the 503A prescription requirement does allow limited “anticipatory” compounding, meaning a small amount prepared ahead based on a pharmacy’s regular prescriptions for that formula. The agency’s interim policy limits anticipatory compounding to a 30-day supply based on the previous year’s prescriptions.
Who Inspects a 503A Pharmacy
State boards of pharmacy are the primary regulators for 503A pharmacies, according to the FDA’s compounding questions and answers. The FDA can still inspect these pharmacies for routine surveillance and when someone reports a problem.
Most states enforce standards from the United States Pharmacopeia: USP <795> for non-sterile preparations like capsules and creams, and USP <797> for sterile preparations, with a revised <797> official since November 1, 2023. Oversight still varies, and a 2018 Pew report on state oversight of compounding found wide differences, even as <797>-level requirements had spread to 43 states.
Limits That Protect Patients
Section 503A also restricts what goes into a compounded medication. Bulk ingredients generally must meet a USP monograph, be a component of an FDA-approved drug, or appear on the FDA’s 503A bulks list. A 503A pharmacy also cannot regularly make what are essentially copies of commercially available drugs.
What a 503B Outsourcing Facility Does
An outsourcing facility works more like a small-scale manufacturer than a neighborhood pharmacy. Registration with the FDA is voluntary, but a registered 503B facility may compound with or without patient-specific prescriptions and can distribute to hospitals, clinics, and practitioners.
In exchange, it must follow current good manufacturing practice (cGMP), the quality rules drugmakers follow. The FDA’s information page for outsourcing facilities explains that these facilities receive risk-based inspections and submit product reports every June and December. They must also report adverse events, label products “This is a compounded drug,” and generally limit bulk ingredients to the FDA’s 503B bulks list or drugs in shortage.
The category is small. The FDA’s list of registered outsourcing facilities, updated September 8, 2026, holds well under 200 entries. By comparison, a National Academies report cited Pew data showing that more than 32,000 U.S. pharmacies do some compounding, with roughly 7,500 specializing in it.
Where Office-Use Medications Come From
This distinction matters most for medical practices. FDA guidance states that compounding office stock without a patient-specific prescription is not a 503A activity, and it points practices that need office-use medications toward 503B outsourcing facilities.
State law has not always been consistent. Pew’s 2018 review found that 39 states and Washington, D.C., prohibited traditional pharmacies from compounding sterile office stock, while some other states had policies that didn’t match federal law. Prescribers should follow FDA guidance and confirm their own state’s rules.
503A vs. 503B Side by Side: Oversight, Scale, and Safety
Neither category is FDA-approved, and neither is automatically “better.” A 503A pharmacy tailors a medication to one patient under state board oversight, while a 503B facility produces larger batches under FDA cGMP rules for clinics and hospitals. The right fit depends on whether a named patient needs a custom formulation or a practice needs stock.
In any 503A vs. 503B comparison, the practical differences start with the prescription. A 503A pharmacy needs one for an identified patient before it compounds, while a 503B facility can make products without one and ship them to a clinic’s shelf. That rule shapes scale, too: 503A work happens one patient at a time, and 503B work happens in batches.
Oversight differs in kind, not only in degree. A 503A pharmacy answers first to its state board and the USP standards that board enforces, while a 503B facility answers to FDA cGMP rules and inspections. Outsourcing facilities must report adverse events under federal law, which doesn’t impose the same requirement on 503A pharmacies, though state rules vary and anyone can report a problem through the FDA’s MedWatch program.
Why “Not FDA-Approved” Doesn’t Mean “Unregulated”
The FDA states plainly that compounded drugs from either source are not reviewed for safety, effectiveness, or quality before they reach patients. That describes the approval process, not an absence of rules. For 503A pharmacies, state licensing, inspections, USP standards, accreditation, and third-party testing fill much of that role, which is one of several common myths about compounding pharmacies worth clearing up.
“The better question is not 503A or 503B, but whether this pharmacy is licensed, inspected, and transparent.”
How to Tell Which Kind of Pharmacy You’re Using
Ask the pharmacy directly, then verify what it tells you. A 503B outsourcing facility will appear on the FDA’s public list of registered outsourcing facilities. A 503A pharmacy must be licensed by the board of pharmacy in the state where it operates and, if it ships, in the state where your medication is delivered.
Californians can check a pharmacy’s status through the California State Board of Pharmacy’s license verification page. Other states offer similar lookups, and King’s explains nonresident licensing in its post on serving patients across multiple states.
Ask whether the pharmacy compounds sterile preparations, non-sterile preparations, or both, whether it holds independent accreditation, and whether an outside lab tests its work. A well-run pharmacy will answer without hesitation, and one that can’t tell you whether it operates under 503A or 503B is a reason to keep looking.
Where King’s Pharmacy Fits as a 503A Compounding Pharmacy
King’s Pharmacy and Compounding Center in Irvine operates under Section 503A, so every compounded medication starts with a patient-specific prescription. King’s has specialized in customized compounding since 2007 and is licensed in California plus Arizona, Colorado, Florida, Hawaii, Idaho, Nevada, New York, Oregon, Texas, Utah, Washington, and Wisconsin.
Quality checks go beyond the license. King’s is NABP accredited and partners with Eagle Analytics, so its compounds are independently tested for accuracy, potency, and quality. The team prepares custom strengths, gluten-free or dye-free formulas, and alternative dosage forms.
For prescribers in Orange County and beyond, the 503A vs. 503B takeaway is practical. Send patient-specific prescriptions to a 503A pharmacy like King’s, source office stock from a registered 503B outsourcing facility, and find more resources for prescribers on the King’s website.
503A vs 503B: Two Tools for Two Different Jobs
The NECC outbreak reshaped compounding law, and the 503A vs. 503B framework is the result. One pathway serves individual patients under state board oversight, and the other supplies clinics and hospitals under FDA manufacturing rules. Both have a place, and both deserve scrutiny.
For patients, the best approach is to confirm your pharmacy’s license, ask about testing, and keep your prescriber informed. For practices, match the source to the need: a 503A pharmacy for named patients and a 503B facility for office stock.
Have questions about whether a compounded medication is right for you? Talk to your prescribing physician, then connect with the pharmacists at King’s Pharmacy and Compounding Center in Irvine, CA, to get started.
Request a Refill or Contact King’s Pharmacy at 949.387.0780.
Medical disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice. Compounded medications require a valid prescription. Talk with your physician or pharmacist about whether a compounded medication is appropriate for you.
Frequently Asked Questions
Is a 503A or 503B pharmacy safer?
Neither category is automatically safer. 503A pharmacies are overseen mainly by state boards of pharmacy, while 503B outsourcing facilities follow FDA manufacturing rules. Safety depends on the specific pharmacy’s licensing, practices, and testing.
Are compounded medications FDA-approved?
No. Compounded medications from 503A pharmacies and 503B outsourcing facilities are not FDA-approved, so the FDA does not review them for safety, effectiveness, or quality beforehand. They are still regulated through state boards of pharmacy, USP standards, and, for 503B facilities, federal inspection.
Can a 503A pharmacy make medications for a doctor’s office without a patient prescription?
Under FDA guidance, 503A compounding must be based on a prescription for an identified patient, so office stock is not a 503A activity. The FDA directs practices that need office-use medications to 503B outsourcing facilities. State rules can differ, so prescribers should also check with their state board.
How do I check if a compounding pharmacy is licensed or registered?
For a 503A pharmacy, use the license lookup on your state board of pharmacy’s website. To find out if a 503B outsourcing facility is registered, check the FDA’s public list of registered outsourcing facilities. A pharmacy that ships from another state must also be licensed in your state.
Is King’s Pharmacy a 503A or 503B pharmacy?
King’s Pharmacy and Compounding Center operates under Section 503A, preparing medications for individual patients with a valid prescription. It is licensed in 13 states, including California, and is NABP accredited. King’s also partners with Eagle Analytics for independent testing.
